Dr. Reddy’s Expands Formulation Development Capabilities
PTSM: Pharmaceutical Technology Sourcing and Management
Dr. Reddy’s announced that it expanded its facilities to include a formulation development laboratory at its Miyapur, Hyperabad, India plant.
Dr. Reddy’s Custom Pharmaceutical Services (CPS) announced on March 10, 2015 that it expanded its existing facilities with new formulation development capabilities. The expansion will bring the active pharmaceutical ingredient development team and the formulation teams to one location to create a Center of Excellence. The center will include preformulation studies, prototype formulation development, process development, and optimization.
“This new Center of Excellence for formulation development services reflects our ongoing focus to better serve our pharma customers. Access to our integrated expertise and resources will bring their drug product to market in an even quicker and more cost-efficient manner than before,” said Anurag Roy, vice-president, global business head at Dr. Reddy’s CPS, in a press release.
Source: Dr. Reddy’s CPS
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
